99 0

Full metadata record

DC FieldValueLanguage
dc.contributor.author배상철-
dc.date.accessioned2019-11-26T04:50:29Z-
dc.date.available2019-11-26T04:50:29Z-
dc.date.issued2017-06-
dc.identifier.citationRHEUMATOLOGY INTERNATIONAL, v. 37, no. 6, page. 975-982en_US
dc.identifier.issn0172-8172-
dc.identifier.issn1437-160X-
dc.identifier.urihttps://link.springer.com/article/10.1007%2Fs00296-016-3649-2-
dc.identifier.urihttps://repository.hanyang.ac.kr/handle/20.500.11754/114539-
dc.description.abstractTo compare the clinical effectiveness of two treatment strategies for active rheumatoid arthritis (RA) refractory to conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs): starting TNF inhibitors (TNFIs) or changing csDMARDs.We used two nationwide Korean RA registries for patient selection. TNFI users were selected from the BIOPSY, which is an inception cohort of RA patients starting biologic DMARDs. As a control group, we selected RA patients with moderate or high disease activity from the KORONA database whose treatment was changed to other csDMARDs. After comparing baseline characteristics between the two groups in either unmatched or propensity score matched cohorts, we compared potential differences in the 1-year remission rate as a primary outcome and changes in HAQ-DI and EQ-5D scores as secondary outcomes.A total of 356 TNFI starters and 586 csDMARD changers were identified from each registry as unmatched cohorts, and 294 patients were included in the propensity score matched cohort. In the intention-to-treat analysis, TNFI starters had higher 1-year remission rates than csDMARD changers in both unmatched (19.1 vs. 18.4%, p < 0.01) and matched cohorts (19.7 vs. 15.0%, p < 0.01). In per protocol analysis, TNFI starters had much higher remission rates in unmatched (37.2 vs. 28.0%, p = 0.04) and matched cohorts (35.4 vs. 19.1%, p = 0.04). However, in matched cohorts, no significant differences were observed between two groups in HAQ-DI and EQ-5D scores.We compared the clinical effectiveness of the two treatment strategies for active RA refractory to csDMARDs. TNFI starters showed higher 1-year remission rates than csDMARD changers.en_US
dc.description.sponsorshipThis research was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health and Welfare, Republic of Korea (Grant Number : HI16C0061).en_US
dc.language.isoen_USen_US
dc.publisherSPRINGER HEIDELBERGen_US
dc.subjectRheumatoid arthritisen_US
dc.subjectDMARDsen_US
dc.subjectAnti-TNF drugsen_US
dc.subjectHAQen_US
dc.subjectQuality of lifeen_US
dc.titleComparative effectiveness of treatment options after conventional DMARDs failure in rheumatoid arthritisen_US
dc.typeArticleen_US
dc.relation.no6-
dc.relation.volume37-
dc.identifier.doi10.1007/s00296-016-3649-2-
dc.relation.page975-982-
dc.relation.journalRHEUMATOLOGY INTERNATIONAL-
dc.contributor.googleauthorSung, Yoon-Kyoung-
dc.contributor.googleauthorCho, Soo-Kyung-
dc.contributor.googleauthorKim, Dam-
dc.contributor.googleauthorChoi, Chan-Bum-
dc.contributor.googleauthorWon, Soyoung-
dc.contributor.googleauthorBang, So-Young-
dc.contributor.googleauthorCha, Hoon-Suk-
dc.contributor.googleauthorChoe, Jung-Yoon-
dc.contributor.googleauthorChung, Won Tae-
dc.contributor.googleauthorBae, Sang Cheol-
dc.relation.code2017003720-
dc.sector.campusS-
dc.sector.daehakCOLLEGE OF MEDICINE[S]-
dc.sector.departmentDEPARTMENT OF MEDICINE-
dc.identifier.pidscbae-
dc.identifier.orcidhttp://orcid.org/0000-0003-4658-1093-
Appears in Collections:
COLLEGE OF MEDICINE[S](의과대학) > MEDICINE(의학과) > Articles
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE